Peeling the I-Onion to Demystify Pseudoprogression
- PMID: 37699332
- DOI: 10.1016/j.ccell.2023.08.003
Peeling the I-Onion to Demystify Pseudoprogression
Abstract
In this issue of Cancer Cell, Topp et al. analyze data from 799 patients treated with pembrolizumab beyond progression by RECIST 1.1 across six trials. Although 8.9%-24.4% of patients demonstrate a ≥30% reduction in target lesions, conversely 11%-18% of patients had a ≥20% increase. The benefits of treatment beyond progression must be carefully weighed against physical and financial toxicities.
Copyright © 2023 Elsevier Inc. All rights reserved.
Conflict of interest statement
Declaration of interests E.S.T. declares institutional clinical trial support from AstraZeneca and Amgen. L.L.S. has consulting/advisory arrangements with Merck, Pfizer, AstraZeneca, Roche, GlaxoSmithKline, Voronoi, Arvinas, Tessa, Navire, Relay, Daiichi Sanyko, Coherus, Marengo, Tubulis, LTZ Therapeutics, NGM Biotherapeutics, Medicenna; stock ownership of Agios (spouse); leadership position in Treadwell Therapeutics (spouse); and the institution receives clinical trials support from Novartis, Bristol-Myers Squibb, Pfizer, Boerhinger-Ingelheim, GlaxoSmithKline, Roche/Genentech, AstraZeneca, Merck, Celgene, Astellas, Bayer, Abbvie, Amgen, Symphogen, Shattucks, BionTech, 23Me, EMD Serono. Daiichi Sanyko, Medicenna, BioNTech, Gilead, Seattle Genetics, Takeda, and Viracta Therapeutics.
Comment on
-
Tumor dynamics in patients with solid tumors treated with pembrolizumab beyond disease progression.Cancer Cell. 2023 Sep 11;41(9):1680-1688.e2. doi: 10.1016/j.ccell.2023.08.004. Cancer Cell. 2023. PMID: 37699333 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
